Home / Mesenchymal Stem Cells / Human Mesenchymal Stem Cell Functional Identification Kit

Human Mesenchymal Stem Cell Functional Identification Kit

Catalog #: SC006
68 Citations 1 Review Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
SC006
Verification of Multipotency using the Human Mesenchymal Stem Cell Functional Identification Kit. 
1 Image
Product Details
Procedure
Citations (68)
FAQs
Supplemental Products
Reviews (1)
Summary Product Datasheets Data Images Background

Human Mesenchymal Stem Cell Functional Identification Kit Summary

Kit Summary

To verify multipotency of human mesenchymal stem cells by in vitro functional differentiation.

Key Benefits

  • Confirms that the starting MSC population is multipotent
  • Can be used with the Human MSC Verification Flow Kit to define MSCs according to the ISCT recommendations
  • Reliably induces MSC trilineage differentiation using defined supplements
  • Includes premium quality antibodies to confirm differentiation

 

Why Funtionally Verify Human MSC Multipotency In Vitro?

Mesenchymal stem/stromal cells (MSCs) can be characterized based on the expression of specific cell surface markers, the absence of hematopoietic markers, and adherence to plastic in vitro.

To more rigorously determine if a cell is truly an MSC, it is important to also verify its ability to differentiate into adipocytes, chondrocytes, and osteocytes.

Functional verification of MSC multipotency in vitro:

  • Uses defined supplements to drive reproducible trilineage differentiation.
  • Verifies a healthy, multipotent starting MSC population to increase consistency between studies and reduce unwanted experimental variability.
  • Meets one of the three recommended minimal criteria for MSC identification.

 

Mesenchymal Stromal Cells or Mesenchymal Stem Cells?

The term ‘mesenchymal stromal cells’ is commonly used to describe a heterogeneous population of cultured cells that are adherent to plastic, have a distinct morphology, and express a specific set of marker proteins. Within this heterogeneous population are cells referred to as ‘mesenchymal stem cells.’

Mesenchymal stem cells are multipotent, self-renewing cells that have the ability to differentiate into adipocytes, chondrocytes, and osteoblasts when cultured in vitro. Read More about MSC Nomenclature

 

Kit Components

This kit contains the following reagents to drive MSC differentiation and a marker to analyze each of the three differentiated derivatives:

  • Adipogenic Supplement
  • Chondrogenic Supplement
  • Osteogenic Supplement
  • ITS Supplement
  • Adipocyte marker: Goat Anti-Mouse FABP4 Antigen Affinity-purified Polyclonal Antibody
  • Chondrocyte marker: Goat Anti-Human Aggrecan Antigen Affinity-purified Polyclonal Antibody
  • Osteocyte marker: Mouse Anti-Human Osteocalcin Monoclonal Antibody

This kit requires media (not included), such as Human/Mouse/Rat StemXVivo Osteogenic/Adipogenic Base Media (CCM007) or equivalent.

The quantity of each media supplement in this kit is sufficient to make 50 mL of media for differentiation. This is enough media for the differentiation of 16 wells of a 24-well plate for osteogenic and adipogenic lineages and 10 chondrocyte pellets.

Precautions

  • The Adipogenic Supplement contains 95% ethanol and is highly flammable. Keep the container tightly closed, and keep it away from sources of ignition.
  • The acute and chronic effects of over-exposure to the reagents in this kit are unknown. Safe laboratory handling procedures should be followed and protective clothing should be worn when handling kit reagents.
  • The ITS Supplement contains human transferrin. This transferrin was tested at the donor level using an FDA licensed method and found to be non-reactive for anti-HIV-1/2 and Hepatitis B surface antigen. As no testing can offer complete assurance of freedom from infectious agents, this reagent should be handled as if capable of transmitting infection.

 

2006 Proposed Change to MSC Nomenclature

Although mesenchymal stromal cells were once referred to as ‘mesenchymal stem cells’, a change to ‘mesenchymal stromal cells’ was proposed by the International Society for Cellular Therapy in 2006.1

The change in nomenclature originates from two important factors:

  • Methods used to isolate mesenchymal stem cells yield a heterogeneous population of cells with only a fraction of these cells demonstrating multipotency.
  • The absence of direct evidence that mesenchymal stem cells can self-renew and differentiate in vivo.

Use of Mesenchymal Stem and Stromal Cell Terminology

Data supporting MSC self-renewal and multipotency have been obtained using in vitro conditions, which does not adequately reflect the in vivo environment. The lack of in vivo data has led some researchers to question the validity of the term ‘mesenchymal stem cell’ providing further support for the use of ‘mesenchymal stromal cells’ to describe MSCs.2 While ‘mesenchymal stromal cells’ may be the more scientifically accurate term for MSCs, the two terms are often used interchangeably in the literature. R&D Systems recognizes the use of both mesenchymal stem cells and mesenchymal stromal cells and uses ‘MSC’ to indicate mesenchymal stem/stromal cells to account for both designations.

Definitions of Mesenchymal Stromal Cells and Mesenchymal Stem Cells

  • Mesenchymal Stromal Cells – A heterogeneous population of cultured cells with similar characteristics such as the ability to adhere to plastic and the expression of specific marker proteins.
  • Mesenchymal Stem Cells – A subpopulation of mesenchymal stromal cells that have the capacity to self-renew and differentiate into mesodermal lineages when cultured in vitro. The capacity to self-renew and differentiate in vivo has yet to be clearly demonstrated for mesenchymal stem cells.

References

  • Dominici, M. et al. (2006) Cytotherapy 8:315.
  • Keating, A. (2012) Cell Stem Cell 10:709.

Specifications

Shipping Conditions
The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.
Species
Human

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Scientific Data

Cell Proliferation Verification of Multipotency using the Human Mesenchymal Stem Cell Functional Identification Kit.  View Larger

Verification of Multipotency using the Human Mesenchymal Stem Cell Functional Identification Kit.  Human mesenchymal stem cells were cultured in StemXVivo®Mesenchymal Stem Cell Expansion Media (Catalog # CCM004) and differentiation was induced as indicated using the media supplements included in the Human Mesenchymal Stem Cell Functional Identification Kit (Catalog # SC006). The kit also contains a Goat Anti-Mouse FABP-4 Antigen Affinity-purified Polyclonal Antibody (adipocytes), a Goat Anti-Human Aggrecan Antigen Affinity-purified Polyclonal Antibody (chondrocytes), and a Mouse Anti-Human Osteocalcin Monoclonal Antibody (osteocytes) for the confirmation of differentiation status. The cells were stained using the NorthernLightsTM 557-conjugated Donkey Anti-Goat (Catalog # NL001; red) or Anti-Mouse (Catalog # NL007; red) IgG Secondary Antibodies, and the nuclei were counterstained with DAPI (blue).

Assay Procedure

Refer to the product datasheet for complete product details.

Briefly, human MSC multipotency is verified using the following in vitro differentiation procedure:

  • Culture multipotent cells of interest
  • Induce adipocyte, chondrocyte, and osteocyte differentiation using media supplements
  • Evaluate differentiation using mature phenotype marker antibodies and fluorescent ICC
SC006 Protocol Graphic Summary
View Graphic Procedure
 

 

Reagents Provided

Reagents supplied in the Human Mesenchymal Stem Cell Functional Identification Kit (Catalog # SC006):

  • Adipogenic Supplement
  • Chondrogenic Supplement
  • Osteogenic Supplement
  • ITS Supplement
  • Adipocyte marker: Goat Anti-Mouse FABP4 Antigen-affinity Purified Polyclonal Antibody
  • Chondrocyte marker: Goat Anti-Human Aggrecan Antigen-affinity Purified Polyclonal Antibody
  • Osteocyte marker: Mouse Anti-Human Osteocalcin Antigen-affinity Purified Monoclonal Antibody

Note: The quantity of each media supplement in this kit is sufficient to make 50 mL of media for differentiation. 50 mL can be used for 16 wells of a 24-well plate for osteogenic and adipogenic lineages and 10 chondrocyte pellets.

 

Other Supplies Required

Reagents

  • StemXVivo® Osteogenic/Adipogenic Base Media (Catalog # CCM007 or equivalent)
  • D-MEM/F-12 (1X)
  • Phosphate Buffered Saline (PBS)
  • Penicillin-Streptomycin-Glutamate (100X)
  • 4% Paraformaldehyde in PBS
  • 1% BSA in PBS
  • Triton® X-100
  • 10% normal donkey serum
  • Fibronectin (optional; Human Fibronectin, Catalog # 1918-FN, Bovine Fibronectin, Catalog # 1030-FN, or equivalent)
  • Mounting medium (Catalog # CTS011 or equivalent)
  • NorthernLightsTM 557-conjugated Donkey Anti-Goat IgG Secondary Antibody (Catalog # NL001 or equivalent)
  • Deionized or distilled water

Materials

  • Human MSCs
  • 24-well culture plates
  • 12 mm coverslips (Carolina Biologicals, Catalog # 633009 or equivalent)
  • 15 mL centrifuge tubes
  • Pipettes and pipette tips
  • Serological pipettes
  • Glass slides
  • Fine pointed curved forceps
  • Liquid barrier pen

Equipment

  • 37 °C and 5% CO2 incubator
  • Centrifuge
  • Hemocytometer
  • Inverted microscope
  • 2 °C to 8 °C refrigerator
  • 37 °C water bath
  • Fluorescence microscope
  • Cryostat
 

 

Procedure Overview

This protocol has been tested using bone marrow- and/or adipose tissue-derived MSCs. If using a different tissue source or cell line, the protocol below may need to be optimized.

Adipogenic Differentiation

Plate 2.1 x 104 MSCs/cm2 in StemXVivo® Osteogenic/Adipogenic Base Media.

Culture cells to 100% confluency.

Culture cells to 100% confluency.

Replace the medium with Adipogenic Differentiation Medium to induce adipogenesis.

Replace the medium with Adipogenic Differentiation Medium to induce adipogenesis.

Every 2-3 days, replace with fresh Adipogenic Differentiation Medium.

After 14-21 days, adipocytes can be fixed.

 

ICC detection of FABP4.

ICC detection of FABP4.

Osteogenic Differentiation

 

Plate 4.2 x 103 MSCs/cm2 in StemXVivo® Osteogenic/Adipogenic Base Media.

Culture cells to 50-70% confluency.

Plate 4.2 x 103 MSCs/cm 2 in StemXVivo Osteogenic/Adipogenic Base Media.

Replace the medium with Osteogenic Differentiation Medium to induce osteogenesis.

Replace the medium with Osteogenic Differentiation Medium to induce osteogenesis.

Every 3-4 days, replace with fresh Osteogenic Differentiation Medium.

After 14-21 days, osteocytes can be fixed.

 

ICC detection of Osteocalcin.

ICC detection of Osteocalcin.

Chondrogenic Differentiation

 

Transfer 2.5 x 104 MSCs to a 15 mL conical tube.

Centrifuge and resuspend the cells in Chondrogenic Differentiation Media.

Centrifuge the cells but do not remove the medium.

Transfer 2.5 x 104 MSCs to a 15 mL conical tube.

Every 2-3 days, replace with fresh Chondrogenic Differentiation Media.

After 14-21 days, the chondrogenic pellet can be fixed.

Every 2-3 days, replace with fresh Chondrogenic Differentiation Media.

Cryosection the chondrogenic pellet.

 

ICC detection of Aggrecan.

ICC detection of Aggrecan.

Citations for Human Mesenchymal Stem Cell Functional Identification Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

68 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. In Vivo and In Vitro Pro-Fibrotic Response of Lung-Resident Mesenchymal Stem Cells from Patients with Idiopathic Pulmonary Fibrosis
    Authors: Escarrer-Garau, G;Martín-Medina, A;Truyols-Vives, J;Gómez-Bellvert, C;Elowsson, L;Westergren-Thorsson, G;Molina-Molina, M;Mercader-Barceló, J;Sala-Llinàs, E;
    Cells  2024-01-16
  2. Adipose-derived mesenchymal stem cell therapy for reverse bleomycin-induced experimental pulmonary fibrosis
    Authors: Zhao, X;Wu, J;Yuan, R;Li, Y;Yang, Q;Wu, B;Zhai, X;Wang, J;Magalon, J;Sabatier, F;Daumas, A;Zhu, WM;Zhu, N;
    Scientific reports  2023-08-14
  3. Enhanced human periodontal ligament stem cell viability and osteogenic differentiation on two implant materials: An experimental in vitro study
    Authors: El Shafei, SF;Raafat, SN;Farag, EA;
    F1000Research  2023-08-08
  4. Directed differentiation of human iPSCs into mesenchymal lineages by optogenetic control of TGF-? signaling
    Authors: Wu, JY;Yeager, K;Tavakol, DN;Morsink, M;Wang, B;Soni, RK;Hung, CT;Vunjak-Novakovic, G;
    Cell reports  2023-05-12
  5. Mesenchymal stromal cells and alpha-1 antitrypsin have a strong synergy in modulating inflammation and its resolution
    Authors: Han, L;Wu, X;Wang, O;Luan, X;Velander, WH;Aynardi, M;Halstead, ES;Bonavia, AS;Jin, R;Li, G;Li, Y;Wang, Y;Dong, C;Lei, Y;
    Theranostics  2023-05-08
  6. A Mutant Methionyl-tRNA Synthetase-Based toolkit to assess induced-Mesenchymal Stromal Cell secretome in mixed-culture disease models
    Authors: Burgess, JD;Amerna, D;Norton, ES;Parsons, TM;Iii, RBP;Faroqi, AH;Wszolek, ZK;Cazares, HG;Kanekiyo, T;Delenclos, M;McLean, PJ;
    Research square  2023-05-03
  7. Adipose-Derived Stromal Cells within a Gelatin Matrix Acquire Enhanced Regenerative and Angiogenic Properties: A Pre-Clinical Study for Application to Chronic Wounds
    Authors: NC Brembilla, A Modarressi, D André-Lévi, E Brioudes, F Lanza, H Vuagnat, S Durual, L Marger, WH Boehncke, KH Krause, O Preynat-Se
    Biomedicines, 2023-03-22;11(3):.  2023-03-22
  8. Mesenchymal Stem Cells from COPD Patients Are Capable of Restoring Elastase-Induced Emphysema in a Murine Experimental Model
    Authors: C Río, AK Jahn, A Martin-Med, AM Calvo Bota, MT De Francis, PJ Pont Anton, O Gigirey Ca, ÁF Carvajal, C Villena Po, C Gómez Bell, A Iglesias, J Calvo Beni, A Gayà Puig, LA Ortiz, E Sala-Llinà
    International Journal of Molecular Sciences, 2023-03-18;24(6):.  2023-03-18
  9. Effect of Different Sealers on the Cytocompatibility and Osteogenic Potential of Human Periodontal Ligament Stem Cells: An In Vitro Study
    Authors: S Saber, S Raafat, M Elashiry, A El-Banna, E Schäfer
    Journal of Clinical Medicine, 2023-03-17;12(6):.  2023-03-17
  10. Carbonised Human Hair Incorporated in Agar/KGM Bioscaffold for Tissue Engineering Application: Fabrication and Characterisation
    Authors: V Vitus, F Ibrahim, SAA Shamsuddin, N Razali, NAB Noor Azlan, WSWK Zaman
    Polymers, 2022-12-15;14(24):.  2022-12-15
  11. Composite alginate-gelatin hydrogels incorporating PRGF enhance human dental pulp cell adhesion, chemotaxis and proliferation
    Authors: E Anitua, M Zalduendo, M Troya, I Erezuma, I Lukin, R Hernáez-Mo, G Orive
    International journal of pharmaceutics, 2022-03-02;617(0):121631.  2022-03-02
  12. Efficient Isolation and Functional Characterization of Niche Cells from Human Corneal Limbus
    Authors: N Polisetti, L Sharaf, U Schlötzer-, G Schlunck, T Reinhard
    International Journal of Molecular Sciences, 2022-03-02;23(5):.  2022-03-02
  13. Adipose-derived stem cell spheroids are superior to single-cell suspensions to improve fat autograft long-term survival
    Authors: S El Harane, S Durual, T Braschler, D André-Lévi, N Brembilla, KH Krause, A Modarressi, O Preynat-Se
    Journal of Cellular and Molecular Medicine, 2022-02-11;0(0):.  2022-02-11
  14. A Robust and Highly Efficient Approach for Isolation of Mesenchymal Stem Cells From Wharton's Jelly for Tissue Repair
    Authors: S Zheng, Y Gao, K Chen, Y Liu, N Xia, F Fang
    Cell Transplantation, 2022-01-01;31(0):9636897221084.  2022-01-01
  15. Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence
    Authors: Q Heydt, C Xintaropou, A Clear, M Austin, I Pislariu, F Miraki-Mou, P Cutillas, K Korfi, M Calaminici, W Cawthorn, K Suchacki, A Nagano, JG Gribben, M Smith, JD Cavenagh, H Oakervee, A Castleton, D Taussig, B Peck, A Wilczynska, L McNaughton, D Bonnet, F Mardakheh, B Patel
    Nature Communications, 2021-09-17;12(1):5507.  2021-09-17
  16. Does TBC1D4 (AS160) or TBC1D1 Deficiency Affect the Expression of Fatty Acid Handling Proteins in the Adipocytes Differentiated from Human Adipose-Derived Mesenchymal Stem Cells (ADMSCs) Obtained from Subcutaneous and Visceral Fat Depots?
    Authors: A Mik?osz, B ?ukaszuk, E Supruniuk, K Grubczak, M Moniuszko, B Choroma?sk, P My?liwiec, A Chabowski
    Cells, 2021-06-16;10(6):.  2021-06-16
  17. Isolation and characterization of bone marrow-derived mesenchymal stem cells in Xenopus laevis
    Authors: R Otsuka-Yam, M Kitada, Y Kuroda, Y Kushida, S Wakao, M Dezawa
    Stem Cell Research, 2021-04-08;53(0):102341.  2021-04-08
  18. Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma
    Authors: J Jazowiecka, A Hadrys, MM Rahman, G McFadden, W Fidyk, E Chmielik, M Pazdzior, M Grajek, V Kozik, A Sochanik
    Cancers, 2021-03-19;13(6):.  2021-03-19
  19. Proinflammatory cytokines and ARDS pulmonary edema fluid induce CD40 on human mesenchymal stromal cells-A potential mechanism for immune modulation
    Authors: EM Wilfong, R Croze, X Fang, M Schwede, E Niemi, GY López, JW Lee, MC Nakamura, MA Matthay
    PLoS ONE, 2020-10-06;15(10):e0240319.  2020-10-06
  20. Assessment and Comparison of the Efficacy of Methotrexate, Prednisolone, Adalimumab, and Tocilizumab on Multipotency of Mesenchymal Stem Cells
    Authors: S Liu, T Kiyoi, M Ishida, M Mogi
    Front Pharmacol, 2020-07-03;11(0):1004.  2020-07-03
  21. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis
    Authors: J Wu, D Song, Z Li, B Guo, Y Xiao, W Liu, L Liang, C Feng, T Gao, Y Chen, Y Li, Z Wang, J Wen, S Yang, P Liu, L Wang, Y Wang, L Peng, GN Stacey, Z Hu, G Feng, W Li, Y Huo, R Jin, N Shyh-Chang, Q Zhou, L Wang, B Hu, H Dai, J Hao
    Cell Res., 2020-06-16;0(0):.  2020-06-16
  22. Chemical-defined medium supporting the expansion of human mesenchymal stem cells
    Authors: J Xu, W Lian, J Chen, W Li, L Li, Z Huang
    Stem Cell Res Ther, 2020-03-19;11(1):125.  2020-03-19
  23. Tunable hydrogels for mesenchymal stem cell delivery: integrin-induced transcriptome alterations and hydrogel optimization for human wound healing
    Authors: AI Marusina, AA Merleev, JI Luna, L Olney, NE Haigh, D Yoon, C Guo, EM Ovadia, M Shimoda, G Luxardi, S Boddu, NN Lal, Y Takada, KS Lam, R Liu, RR Isseroff, S Le, JA Nolta, AM Kloxin, E Maverakis
    Stem Cells, 2019-11-23;0(0):.  2019-11-23
  24. Improving the viability of tissue-resident stem cells using an organ-preservation solution
    Authors: T Suzuki, C Ota, N Fujino, Y Tando, S Suzuki, M Yamada, T Kondo, Y Okada, H Kubo
    FEBS Open Bio, 2019-11-18;0(0):.  2019-11-18
  25. Tendon contains more stem cells than bone at the rotator cuff repair site
    Authors: TM Campbell, P Lapner, FJ Dilworth, MA Sheikh, O Laneuville, H Uhthoff, G Trudel
    J Shoulder Elbow Surg, 2019-04-26;0(0):.  2019-04-26
  26. Combination of polyetherketoneketone scaffold and human mesenchymal stem cells from temporomandibular joint synovial fluid enhances bone regeneration
    Authors: Y Lin, M Umebayashi, MN Abdallah, G Dong, MG Roskies, YF Zhao, M Murshed, Z Zhang, SD Tran
    Sci Rep, 2019-01-24;9(1):472.  2019-01-24
  27. Serum-Free Manufacturing of Mesenchymal Stem Cell Tissue Rings Using Human-Induced Pluripotent Stem Cells
    Authors: TS Winston, K Suddhapas, C Wang, R Ramos, P Soman, Z Ma
    Stem Cells Int, 2019-01-15;2019(0):5654324.  2019-01-15
  28. Comparative analysis of mesenchymal stem cells derived from amniotic membrane, umbilical cord, and chorionic plate under serum-free condition
    Authors: J Ma, J Wu, L Han, X Jiang, L Yan, J Hao, H Wang
    Stem Cell Res Ther, 2019-01-11;10(1):19.  2019-01-11
  29. Generation of a human Ocular Albinism type 1 iPSC line, SEIi001-A, with a mutation in GPR143.
    Authors: Baulier E, Garcia Diaz A, Corneo B, Farber D
    Stem Cell Res, 2018-11-28;33(0):274-277.  2018-11-28
  30. Multilineage-differentiating stress-enduring (Muse)-like cells exist in synovial tissue
    Authors: E Toyoda, M Sato, T Takahashi, M Maehara, Y Nakamura, G Mitani, T Takagaki, K Hamahashi, M Watanabe
    Regen Ther, 2018-11-20;10(0):17-26.  2018-11-20
  31. Characterization of the interaction between human decidua parietalis mesenchymal stem/stromal cells and natural killer cells
    Authors: MH Abumaree, E Bahattab, A Alsadoun, A Al Dosaima, FM Abomaray, T Khatlani, B Kalionis, MF El-Muzaini, AO Alawad, AS AlAskar
    Stem Cell Res Ther, 2018-04-12;9(1):102.  2018-04-12
  32. Evaluation of the effects of ascorbic acid on metabolism of human mesenchymal stem cells
    Authors: K Fujisawa, K Hara, T Takami, S Okada, T Matsumoto, N Yamamoto, I Sakaida
    Stem Cell Res Ther, 2018-04-06;9(1):93.  2018-04-06
  33. Comparison of the bone regeneration ability between stem cells from human exfoliated deciduous teeth, human dental pulp stem cells and human bone marrow mesenchymal stem cells
    Authors: K Nakajima, R Kunimatsu, K Ando, T Ando, Y Hayashi, T Kihara, T Hiraki, Y Tsuka, T Abe, M Kaku, H Nikawa, T Takata, K Tanne, K Tanimoto
    Biochem. Biophys. Res. Commun., 2018-03-11;497(3):876-882.  2018-03-11
  34. Comparative characterization of SHED and DPSCs during extended cultivation in�vitro
    Authors: H Wang, Q Zhong, T Yang, Y Qi, M Fu, X Yang, L Qiao, Q Ling, S Liu, Y Zhao
    Mol Med Rep, 2018-03-09;0(0):.  2018-03-09
  35. Nano-loaded human umbilical cord mesenchymal stem cells as targeted carriers of doxorubicin for breast cancer therapy
    Authors: S Cao, J Guo, Y He, M Alahdal, S Tang, Y Zhao, Z Yang, H Gao, W Hu, H Jiang, L Qin, L Jin
    Artif Cells Nanomed Biotechnol, 2018-02-19;0(0):1-11.  2018-02-19
  36. Optimized Longitudinal Monitoring of Stem Cell Grafts in Mouse Brain Using a Novel Bioluminescent/Near Infrared Fluorescent Fusion Reporter
    Authors: L Mezzanotte, JD Iljas, I Que, A Chan, E Kaijzel, R Hoeben, C Löwik
    Cell Transplant, 2017-12-01;26(12):1878-1889.  2017-12-01
  37. Rapid Rapamycin-Only Induced Osteogenic Differentiation of Blood-Derived Stem Cells and Their Adhesion to Natural and Artificial Scaffolds
    Authors: C Arianna, C Eliana, A Flavio, R Marco, D Giacomo, S Manuel, B Elena, G Alessandra
    Stem Cells Int, 2017-07-26;2017(0):2976541.  2017-07-26
  38. Mesenchymal Stem Cells Induce Epithelial to Mesenchymal Transition in Colon Cancer Cells through Direct Cell-to-Cell Contact
    Authors: H Takigawa, Y Kitadai, K Shinagawa, R Yuge, Y Higashi, S Tanaka, W Yasui, K Chayama
    Neoplasia, 2017-04-20;19(5):429-438.  2017-04-20
  39. Identification of multipotent stem cells in human brain tissue following stroke
    Authors: K Tatebayash, Y Tanaka, A Nakano-Doi, R Sakuma, S Kamachi, M Shirakawa, K Uchida, H Kageyama, T Takagi, S Yoshimura, T Matsuyama, T Nakagomi
    Stem Cells Dev, 2017-04-19;0(0):.  2017-04-19
  40. Expression pattern of neurotrophins and their receptors during neuronal differentiation of adipose-derived stem cells in simulated microgravity condition
    Authors: V Zarrinpour, Z Hajebrahim, M Jafarinia
    Iran J Basic Med Sci, 2017-02-01;20(2):178-186.  2017-02-01
  41. Are Adipose-Derived Stem Cells From Liver Falciform Ligaments Another Possible Source of Mesenchymal Stem Cells?
    Authors: SW Lee, JU Chong, SO Min, SY Bak, KS Kim
    Cell Transplant, 2016-11-24;26(5):855-866.  2016-11-24
  42. Human endometrial mesenchymal stem cells exhibit intrinsic anti-tumor properties on human epithelial ovarian cancer cells
    Sci Rep, 2016-11-15;6(0):37019.  2016-11-15
  43. In vitro characterization of human dental pulp stem cells isolated by three different methods
    Authors: Euiseong Kim
    Restor Dent Endod, 2016-10-12;41(4):283-295.  2016-10-12
  44. Label-Free Imaging of Umbilical Cord Tissue Morphology and Explant-Derived Cells
    Stem Cells Int, 2016-09-26;2016(0):5457132.  2016-09-26
  45. TLR3 preconditioning enhances the therapeutic efficacy of umbilical cord mesenchymal stem cells in TNBS-induced colitis via the TLR3-Jagged-1-Notch-1 pathway
    Mucosal Immunol, 2016-09-21;0(0):.  2016-09-21
  46. Equine metabolic syndrome impairs adipose stem cells osteogenic differentiation by predominance of autophagy over selective mitophagy
    J Cell Mol Med, 2016-09-14;0(0):.  2016-09-14
  47. Exendin-4 enhances the differentiation of Wharton's jelly mesenchymal stem cells into insulin-producing cells through activation of various ?-cell markers
    Stem Cell Res Ther, 2016-08-11;7(1):108.  2016-08-11
  48. Transcriptome sequencing wide functional analysis of human mesenchymal stem cells in response to TLR4 ligand
    Sci Rep, 2016-07-22;6(0):30311.  2016-07-22
  49. Human Cardiac Mesenchymal Stromal Cells with CD105+CD34- Phenotype Enhance the Function of Post-Infarction Heart in Mice
    PLoS ONE, 2016-07-14;11(7):e0158745.  2016-07-14
  50. Prospectively Isolated Human Bone Marrow Cell-Derived MSCs Support Primitive Human CD34-Negative Hematopoietic Stem Cells.
    Authors: Matsuoka Y, Nakatsuka R, Sumide K, Kawamura H, Takahashi M, Fujioka T, Uemura Y, Asano H, Sasaki Y, Inoue M, Ogawa H, Takahashi T, Hino M, Sonoda Y
    Stem Cells, 2015-05-01;33(5):1554-65.  2015-05-01
  51. Generation of CCR5-defective CD34 cells from ZFN-driven stop codon-integrated mesenchymal stem cell clones.
    Authors: Manotham, Krissana, Chattong, Supreech, Setpakdee, Anant
    J Biomed Sci, 2015-03-26;22(0):25.  2015-03-26
  52. Umbilical cord mesenchymal stromal cells affected by gestational diabetes mellitus display premature aging and mitochondrial dysfunction.
    Authors: Kim J, Piao Y, Pak Y, Chung D, Han Y, Hong J, Jun E, Shim J, Choi J, Kim C
    Stem Cells Dev, 2015-01-14;24(5):575-86.  2015-01-14
  53. Human adipose-derived mesenchymal stem cells as a new model of spinal and bulbar muscular atrophy.
    Authors: Dossena M, Bedini G, Rusmini P, Giorgetti E, Canazza A, Tosetti V, Salsano E, Sagnelli A, Mariotti C, Gellera C, Navone S, Marfia G, Alessandri G, Corsi F, Parati E, Pareyson D, Poletti A
    PLoS ONE, 2014-11-13;9(11):e112746.  2014-11-13
  54. Gene expression profile analysis of human mesenchymal stem cells from herniated and degenerated intervertebral discs reveals different expression of osteopontin.
    Authors: Marfia G, Navone S, Di Vito C, Tabano S, Giammattei L, Di Cristofori A, Gualtierotti R, Tremolada C, Zavanone M, Caroli M, Torchia F, Miozzo M, Rampini P, Riboni L, Campanella R
    Stem Cells Dev, 2014-10-29;24(3):320-8.  2014-10-29
  55. Magnetic Nanoparticle Based Nonviral MicroRNA Delivery into Freshly Isolated CD105(+) hMSCs.
    Authors: Schade A, Muller P, Delyagina E, Voronina N, Skorska A, Lux C, Steinhoff G, David R
    Stem Cells Int, 2014-03-31;2014(0):197154.  2014-03-31
  56. Amide-type local anesthetics and human mesenchymal stem cells: clinical implications for stem cell therapy.
    Authors: Dregalla, Ryan C, Lyons, Nicolett, Reischling, Patrick, Centeno, Christop
    Stem Cells Transl Med, 2014-01-16;3(3):365-74.  2014-01-16
  57. Coculture of human nucleus pulposus cells with multipotent mesenchymal stromal cells from human bone marrow reveals formation of tunnelling nanotubes.
    Authors: Lehmann T, Filipiak K, Juzwa W, Sujka-Kordowska P, Jagodzinski P, Zabel M, Glowacki J, Misterska E, Walczak M, Glowacki M
    Mol Med Rep, 2013-11-21;9(2):574-82.  2013-11-21
  58. WNT3A promotes hematopoietic or mesenchymal differentiation from hESCs depending on the time of exposure.
    Authors: Gertow K, Hirst C, Yu Q, Ng E, Pereira L, Davis R, Stanley E, Elefanty A
    Stem Cell Reports, 2013-06-04;1(1):53-65.  2013-06-04
  59. Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling.
    Authors: Reinhardt P, Glatza M, Hemmer K, Tsytsyura Y, Thiel C, Hoing S, Moritz S, Parga J, Wagner L, Bruder J, Wu G, Schmid B, Ropke A, Klingauf J, Schwamborn J, Gasser T, Scholer H, Sterneckert J
    PLoS ONE, 2013-03-22;8(3):e59252.  2013-03-22
  60. Human embryonic stem cell derived mesenchymal progenitors express cardiac markers but do not form contractile cardiomyocytes.
    Authors: Raynaud C, Halabi N, Elliott D, Pasquier J, Elefanty A, Stanley E, Rafii A
    PLoS ONE, 2013-01-16;8(1):e54524.  2013-01-16
  61. Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms.
    Authors: Zhu X, Urbieta-Caceres V, Krier J, Textor S, Lerman A, Lerman L
    Stem Cells, 2013-01-01;31(1):117-25.  2013-01-01
  62. Identification of spectral modifications occurring during reprogramming of somatic cells.
    Authors: Sandt C, Feraud O, Oudrhiri N, Bonnet ML, Meunier MC, Valogne Y, Bertrand A, Raphael M, Griscelli F, Turhan AG, Dumas P, Bennaceur-Griscelli A
    PLoS ONE, 2012-04-13;7(4):e30743.  2012-04-13
  63. Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells.
    Authors: Griscelli F, Feraud O, Oudrhiri N, Gobbo E, Casal I, Chomel JC, Bieche I, Duvillard P, Opolon P, Turhan AG, Bennaceur-Griscelli A
    Am. J. Pathol., 2012-03-13;180(5):2084-96.  2012-03-13
  64. Efficient differentiation of human pluripotent stem cells into mesenchymal stem cells by modulating intracellular signaling pathways in a feeder/serum-free system.
    Authors: Tran NT, Trinh QM, Lee GM
    Stem Cells Dev., 2011-09-27;21(7):1165-75.  2011-09-27
  65. Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions.
    Authors: Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Crippa S, Sohni A, Roberts SJ, Luyten FP, Van Gool SW, Sampaolesi M, Delforge M, Luttun A, Verfaillie CM
    Stem Cells, 2011-05-01;29(5):871-82.  2011-05-01
  66. Isolation and characterization of synovial mesenchymal stem cells.
    Authors: Harvanova D, Tothova T, Sarissky M, Amrichova J, Rosocha J
    Folia Biol. (Praha), 2011-01-01;57(3):119-24.  2011-01-01
  67. Isolation of alveolar epithelial type II progenitor cells from adult human lungs.
    Authors: Fujino N, Kubo H, Suzuki T
    Lab. Invest., 2010-11-15;91(0):363-78.  2010-11-15
  68. Collection and culture of alveolar bone marrow multipotent mesenchymal stromal cells from older individuals.
    Authors: Han J, Okada H, Takai H, Nakayama Y, Maeda T, Ogata Y
    J. Cell. Biochem., 2009-08-15;107(6):1198-204.  2009-08-15

FAQs

  1. Can the Human Mesenchymal Stem Cell Functional Identification Kit (Catalog # SC006) be used with non-human primate mesenchymal stem cells?

    • It is likely that the antibodies included in the kit are cross-reactive to other primates. The supplements included in the kit are not intended to be species-specific. However, the kit has not been tested with primate mesenchymal stem cells

  2. For the Human Mesenchymal Stem Cell Functional Identification Kit (Catalog # SC006), how can induction of differentiation be monitored?

    • For adipogenic differentiation, the appearance of vacuoles in cells after 5-7 days is a sign of differentiation and can be monitored by microscopic examination of the cells. For osteogenic differentiation, the beginning of cell detachment after about 14 days is a sign of differentiation. Cell detachment should be monitored in this case. For chondrogenic differentiation, there isn't an exact marker to look for other than fixing and staining the frozen pellet between differentiation days 14 - 21. The exact choice of time may take some empirical testing.

  3. In the Human Mesenchymal Stem Cell Functional Identification Kit (Catalog # SC006), are Part #'s 90415, 390416, and 390417 the same as the StemXVivo® Human Adipogenic Supplement (Catalog # CCM011), StemXVivo® Human Osteogenic Supplement (Catalog # CCM008), and StemXVivo® Human Chondrogenic Supplement (Catalog # CCM006), respectively?

    • Yes, the StemXVivo® Human Adipogenic Supplement (Catalog # CCM011), StemXVivo®  Human Osteogenic Supplement (Catalog # CCM008), and StemXVivo® Human Chondrogenic Supplement (Catalog # CCM006) are the same as Part #'s 390415, 390416, and 390417, respectively, in the Human Mesenchymal Stem Cell Functional Identification Kit (Catalog # SC006).

  4. Are there any experimental tips/hints for successful chondrogenic differentiation of mesenchymal stem cells?

    • The following tips/hints are useful for chondrogenic differentiation:

      a) The mesenchymal stem cells (MSCs) should not be from a late passage (passage 8 or less), b) if using the Human Mesenchymal Stem Cell Functional Identification Kit (Catalog # SC006) or the StemXVivo® Chondrogenic Supplement (Catalog # CCM006), use the starting MSC cell number that is indicated in the protocol, c) Early during chondrogenic differentiation a pellet should form. As differentiation progresses, the pellet will grow and take up a ball-like appearance. d) The pellet should not attach to the tube, therefore care should be taken to not dislodge it while changing media.

View all Stem Cell Product FAQs
Loading...

Reviews for Human Mesenchymal Stem Cell Functional Identification Kit

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human Mesenchymal Stem Cell Functional Identification Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human Mesenchymal Stem Cell Functional Identification Kit
By Anonymous on 10/17/2016

The MSC’s were generated from induced pluripotent stem cells and then tested using your kit for its potential to differentiate along the adipogenic and chondrogenic lineages.

Human Mesenchymal Stem Cell Functional Identification Kit SC006